Home › Research › Treatments
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study
Rogers SL, Friedhoff LT.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1998-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The long-term efficacy and safety of donepezil (up to 10 mg/day) was evaluated in a multicentre, non-randomised, open-label extension study of 133 patients with mild to moderate Alzheimer's disease (AD) who had completed a previous 14-week double-blind, placebo-controlled trial of donepezil. Assessments were conducted at three-weekly intervals for 12 weeks, then 12-weekly for up to 192 weeks. Efficacy, assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating-Sum of the Boxes (CDR-SB), was examined in comparison with published data of untreated AD patients.
What this study adds
Evidence grade: High
This is a trial of 133 participants. This open-label extension study followed 133 patients with mild to moderate Alzheimer's disease taking donepezil for up to 192 weeks, comparing results with published data on untreated patients. It reports on an existing drug's long-term use, not on curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rogers, S. L., & Friedhoff, L. T. (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. https://doi.org/10.1016/s0924-977x(97)00079-5
Vancouver
Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1998. doi:10.1016/s0924-977x(97)00079-5. PMID: 9452942.
BibTeX
@article{rogers1998-9452942,
author = {Rogers, S. L. and Friedhoff, L. T.},
title = {{Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study}},
journal = {European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
year = {1998},
doi = {10.1016/s0924-977x(97)00079-5},
pmid = {9452942},
url = {https://doi.org/10.1016/s0924-977x(97)00079-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Assessments were conducted at three-weekly intervals for 12 weeks, then 12-weekly for up to 192 weeks.
- Efficacy, assessed by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating-Sum of the Boxes (CDR-SB), was examined in comparison with published data of untreated AD patients.
- Safety was monitored by physical examinations, laboratory tests and vital sign measurements.
- Results of this interim analysis (at 98 weeks) show that donepezil produced improvements in cognition which remained superior to baseline for 38 weeks.
Why it matters
This open-label extension study followed 133 patients with mild to moderate Alzheimer's disease taking donepezil for up to 192 weeks, comparing results with published data on untreated patients. It reports on an existing drug's long-term use, not on curing or preventing the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designopen-label trial
- Participants133
- Evidence strengthHigh
How this study scored 65/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology) |
| Journal's citation record | 2 / 4 | European Neuropsychopharmacology: journal h-index 158 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1998 — older than 20 years, still counted |
| Sample size | 2 / 4 | 133 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 293 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.8 citations a year over 30 year(s) since 1998 |
| Impact for its field and year | 5 / 6 | Cited 33.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Lawrence T. Friedhoff: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Eisai (United States): institution h-index 251 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 9452942) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.